(A) High levels of Mirk expression were visible in tumor cell lines, including osteosarcoma (U-2OS, KHOS), uterine sarcoma (MES-SA), chondrosarcoma (CS-1) synovial sarcoma (SS-1), Ewing sarcoma (TC-71) and ovarian cancer (SKOV-3, 3A, 2008). staining (high levels of Mirk protein expression) is significantly shorter than those with Mirk low staining and moderate staining. This highlights Mirks potential to serve as a promising target for molecular therapy in the treatment of osteosarcoma. == Introduction == Osteosarcoma is the most common primary malignant tumor of bone with high metastatic potential (1,2). Treatment of osteosarcoma requires therapy incorporating surgery and systemic chemotherapy. Chemotherapy protocols involve several chemotherapeutic brokers, including doxorubicin, cisplatin, ifosfamide and methotrexate (3). However, if these brokers are unable to solicit a favorable response, then any further therapeutic options are limited. One-third of patients with localized osteosarcoma experience recurrent or progressive disease (4) and the average survival period after a recurrence is usually <1 12 months (5). Therefore, to improve the survival rate of osteosarcoma patients and to better their overall well being, it is usually imperative to constantly develop novel therapeutic strategies. Recently, research on osteosarcoma has been focused on identifying novel therapeutic CYN-154806 targets and prognostic markers. Several molecular targets are currently under evaluation for osteosarcoma, including insulin-like growth factor 1 receptor, epidermal growth factor receptor, signal transducer and activator of transcription 3 and mammalian target of rapamycin (68). There is, however, insufficient data to allow any of these targets to be recommended as prognostic factors or therapeutic targets. One method for the identification of novel prognostic or therapeutic targets is utilizing a RNA interference screen. RNA interference suppresses gene expression in mammalian cells, and chemically synthesized small interference RNAs (siRNAs) have become essential CYN-154806 tools for biological studies. Indeed, screens done in human cells using libraries of synthetic siRNAs targeting defined gene families have identified various kinases required for growth, survival and drug resistance in human malignancy cells (9,10). This powerful new technique is also applicable to osteosarcoma cell lines in order to identify cellular signaling pathways that may be essential for osteosarcoma cell growth and survival and ultimately may be targets for novel therapy. The human kinome contains at least 600 protein kinases that phosphorylate proteins at 250 000 or more sites (1113). Kinases are dysregulated in many cancers, including osteosarcoma. Given that protein phosphorylation regulates cancer cell survival, strategies for targeting kinases are paramount for improved therapeutic intervention (13). It has been shown that this suppression of some kinases, such as tyrosine kinases Bcr-abl and Her2 (14,15), and the serine/threonine kinases Raf, Akt and mammalian target of rapamycin, inhibit tumor cell growth and proliferation, suggesting that development of inhibitors that target these kinases may lead to new anticancer strategies (1618). The role of kinases in osteosarcoma is not currently well comprehended, and a thorough study of these proteins and their functions is probably to contribute to the discovery and development of new therapeutic approaches. Kinases, such as insulin-like growth factor 1 receptor, phosphoinositide 3-kinases/protein kinase B, platelet-derived growth factor receptor and mammalian target of rapamycin, have been found to be highly expressed in different sarcomas, particularly in the advanced stages (1923), and identification of novel kinases whose inhibition induces osteosarcoma cell lethality would be of high value in clinical management. In the present study, the functions of protein kinases in supporting osteosarcoma cell growth are examined using a human kinase short hairpin RNA (shRNA) library. PRKCA Our screens elucidate that decreased expression of minibrain-related kinase (Mirk) (Dyrk1B) can inhibit growth and induce apoptosis in osteosarcoma CYN-154806 cells. Additionally, we observe a high endogenous level of Mirk expression in osteosarcoma cell CYN-154806 lines and osteosarcoma tissue. The relative level of Mirk expression in tumors is usually closely correlated with poor prognosis.